Lunai Bioworks Raises $20 M to Add Dual Brain‑Delivery Platforms for Alzheimer’s and Biodefense

*TL;DR: Lunai Bioworks closed a $20 million Series B preferred stock issuance on May 1, 2026 to buy brain‑delivery patents, adding a BBB‑crossing prodrug system and a nose‑to‑brain (N2B) pathway that will feed its Alzheimer’s and biodefense programs.

Context

The biotech’s latest financing follows a March 2026 purchase of a blood‑brain barrier (BBB) delivery platform that lifted its share price by 22.94% the next trading day. The new capital is earmarked for a second acquisition that pairs the BBB prodrug technology with an N2B route that bypasses the BBB via olfactory and trigeminal nerves. Both methods aim to increase drug concentrations in the central nervous system (CNS) while limiting systemic exposure.

Key Facts

- On May 1, 2026 Lunai issued $20 million of Series B preferred stock, the proceeds funding the acquisition of CNS delivery and neurotherapeutic intellectual property. - The assets will be housed in a wholly‑owned subsidiary to centralize development of Alzheimer’s treatments, 505(b)(2) reformulations, combination therapies, and biodefense countermeasures. - CEO David Weinstein said the deal “combines complementary CNS delivery methods to overcome a major hurdle in neurological drug development and expands therapy development, partnership, licensing, and funding opportunities.” - The company must still satisfy Nasdaq’s $2.5 million stockholders’ equity rule; the Panel’s formal decision is pending.

What It Means

The dual‑delivery portfolio gives Lunai a rare capability: a chemically modified prodrug that can cross the BBB and an intranasal route that delivers agents directly to the brain. In Alzheimer’s research, randomized controlled trials (RCTs) of intranasal insulin in 2020 (n = 104) showed modest cognitive benefits, suggesting that N2B delivery can achieve therapeutic levels quickly. By pairing such a route with BBB‑penetrant molecules, Lunai could test combination regimens in smaller cohorts, potentially accelerating proof‑of‑concept studies.

For biodefense, rapid CNS access is critical for counteracting neurotoxic threats. A 2019 cohort study (n = 78) of a nerve‑agent antidote delivered intranasally demonstrated faster symptom reversal than intravenous dosing, underscoring the strategic value of N2B technology.

Investors should watch the Nasdaq Panel’s equity ruling, the timeline for integrating the two delivery platforms, and any partnership announcements that leverage the new IP. Successful validation could position Lunai as a go‑to partner for firms seeking to move CNS drugs through the historically high‑failure barrier of brain penetration.